13F value (AUM)
$20.0B
Baker Bros. Advisors
BAKER BROS. ADVISORS LP
$20.0B
13F long value · 2026-Q2Positions84
CategoryAsset Manager
Quarters tracked9
● #350 of 581 by 13F value
Size rank 4/10
7 NEW2 ADD3 2×+3 TRIM8 EXIT
Snapshot
Baker Bros. Advisors's 13F portfolio at a glance — size, concentration and this quarter's activity.
Positions
84 (6 unmapped)
Top 84 weight
99.9%
Quarters tracked
9
Latest 13F filed
Aug 14, 2026
New positions
7
Exits / near-exits
8
13F value by quarter
Total reported long value each quarter — fund flows plus market moves.
Top holdings — 2026-Q2
The fund's largest reported positions. The 84 shown cover 99.9% of the portfolio.
| Ticker | Issuer | Weight | Value | Shares | Since 2026-Q2 |
|---|---|---|---|---|---|
| INCY | Incyte Corporation | 17.5% | $3.5B | 30.8M | -15.6% |
| ONC | BeOne Medicines Ltd. | 12.6% | $2.5B | 8.8M | +4.9% |
| RVMD | Revolution Medicines, Inc. | 10.7% | $2.1B | 11.4M | -29.7% |
| MDGL | Madrigal Pharmaceuticals, Inc. | 5.8% | $1.2B | 2.1M | -3.1% |
| ACAD | ACADIA Pharmaceuticals Inc. | 5.4% | $1.1B | 42.9M | -11.9% |
| KYMR | Kymera Therapeutics, Inc. | 5.0% | $992.7M | 8.7M | -24.4% |
| INSM | Insmed Incorporated | 4.7% | $937.8M | 8.8M | +27.5% |
| CELC | Celcuity Inc. | 4.2% | $828.2M | 7.9M | +20.1% |
| KOD | Kodiak Sciences Inc. | 3.9% | $776.1M | 19.9M | +13.2% |
| RYTM | Rhythm Pharmaceuticals, Inc. | 3.1% | $622.3M | 5.6M | -23.3% |
| PRAX | Praxis Precision Medicines, Inc. | 2.9% | $587.0M | 1.8M | -1.1% |
| — | Alkermes plc | 2.6% | $524.6M | 10.0M | — |
| SMMT | Summit Therapeutics Inc. | 2.4% | $477.7M | 32.8M | +51.8% |
| GRAL | GRAIL, Inc. | 1.4% | $275.0M | 4.0M | -19.4% |
| ABCL | AbCellera Biologics Inc. | 1.3% | $259.1M | 33.0M | -47.0% |
Quarterly changes — 2026-Q2
What Baker Bros. Advisors opened, added, trimmed and exited this quarter, largest dollar moves first.
| Action | Ticker | Issuer | Prev shares | Curr shares | Change | Value Δ |
|---|---|---|---|---|---|---|
| EXIT | ABVX | Abivax S.A. | 875.8K | 0 | -100.0% | -$97.5M |
| TRIM | EWTX | Edgewise Therapeutics, Inc. | 6.6M | 3.7M | -43.7% | -$56.7M |
| ADD | IDYA | IDEAYA Biosciences, Inc. | 3.9M | 5.0M | +26.9% | +$55.2M |
| EXIT | SYRE | Spyre Therapeutics, Inc. | 1.0M | 0 | -100.0% | -$50.4M |
| 2×+ | RLAY | Relay Therapeutics, Inc. | 1.2M | 2.8M | +143.7% | +$41.3M |
| NEW | FTH | Faeth Therapeutics, Inc. | — | 1.3M | — | +$32.2M |
| EXIT | CNTA | Centessa Pharmaceuticals plc | 670.8K | 0 | -100.0% | -$26.6M |
| ADD | CLDX | Celldex Therapeutics, Inc. | 665.4K | 1.2M | +77.7% | +$22.9M |
| EXIT | IMCR | Immunocore Holdings plc | 734.4K | 0 | -100.0% | -$22.1M |
| EXIT | CTNM | Contineum Therapeutics, Inc. | 1.4M | 0 | -100.0% | -$18.6M |
Conviction over time
Portfolio weight of the current top long holdings, quarter by quarter — rising weight = growing conviction.